Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers - Concepedia

Concepedia

Publication | Closed Access

Pharmacokinetic Characterization of Different Dose Combinations of Coadministered Tipranavir and Ritonavir in Healthy Volunteers

64

Citations

13

References

2004

Year

Thomas R. MacGregor, John P. Sabo, Stephen H. Norris, Philip A. Johnson, Lawrence Galitz, Scott McCallister

HIV Clinical Trials

Abstract

This phase 1 study demonstrated that RTV-boosted TPV achieves concentrations that are expected to be effective in treating drug-experienced patients.

References

	Year	Citations
Antiretroviral-Drug Resistance among Patients Recently Infected with HIV Susan J. Little, Sarah Holte, Jean‐Pierre Routy, New England Journal of Medicine	2002	1.1K
Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. Paul B. Watkins, Scott A Murray, L G Winkelman, Journal of Clinical Investigation PharmacotherapyExperimental PharmacologyPhysiologically-based Pharmacokinetic ModelingOxidative StressP-450iiia Inducers Dexamethasone	1989	351
Tipranavir (PNU-140690): A Potent, Orally Bioavailable Nonpeptidic HIV Protease Inhibitor of the 5,6-Dihydro-4-hydroxy-2-pyrone Sulfonamide Class Steve R. Turner, Joseph W. Strohbach, Rubén Tommasi, Journal of Medicinal Chemistry	1998	293
Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir. T. Koudriakova, Eugenia Iatsimirskaia, Ilya Utkin, PubMed Cytochrome P4503aMetabolomic ProfilingAntiviral DrugAntiviral Drug DevelopmentEnzyme Kinetic Parameters	1998	243
Potent Inhibition of the Cytochrome P-450 3A-Mediated Human Liver Microsomal Metabolism of a Novel HIV Protease Inhibitor by Ritonavir: A Positive Drug-Drug Interaction Gondi Kumar, J.C. Dykstra, Ellen Roberts, Drug Metabolism and Disposition	1999	166
Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples Brendan Larder, Kurt Hertogs, Stuart Bloor, AIDS	2000	157
Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor Susan M. Poppe, Dea Slade, K. T. Chong, Antimicrobial Agents and Chemotherapy Dihydropyrone Pnu-140690ImmunologyPharmacotherapyAntiviral DrugDrug Resistance	1997	121
Susceptibility to PNU-140690 (Tipranavir) of Human Immunodeficiency Virus Type 1 Isolates Derived from Patients with Multidrug Resistance to Other Protease Inhibitors Stefano Rusconi, Simona La Seta Catamancio, Paola Citterio, Antimicrobial Agents and Chemotherapy	2000	91
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens Julio Montaner, P. Richard Harrigan, Natalie Jahnke, AIDS	2001	89
Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers Yasmin Khaliq, Keith Gallicano, Christine Tisdale, British Journal of Clinical Pharmacology Drug InteractionsRitonavir 200Therapeutic Drug MonitoringPharmacokinetic ModelingPharmacological Study	2001	76

Page 1